Zobrazeno 1 - 10 of 369 pro vyhledávání: '"BLUMENBERG, V."'
1
Akademický článek
Predictive value of pre-infusion tumor growth rate for the occurrence and severity of CRS and ICANS in lymphoma under CAR T-cell therapy.
Autor: Winkelmann M; Department of Radiology, University Hospital, LMU Munich, Munich, Germany., Blumenberg V; Laboratory for Translational Cancer Immunology, Gene Center of the LMU Munich, Munich, Germany.; German Cancer Consortium (DKTK) and Bavarian Center for Cancer Research (BZKF), Partner Site Munich, Munich, Germany.; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany., Rejeski K; Laboratory for Translational Cancer Immunology, Gene Center of the LMU Munich, Munich, Germany.; German Cancer Consortium (DKTK) and Bavarian Center for Cancer Research (BZKF), Partner Site Munich, Munich, Germany.; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany., Quell C; Department of Radiology, University Hospital, LMU Munich, Munich, Germany., Bücklein VL; Laboratory for Translational Cancer Immunology, Gene Center of the LMU Munich, Munich, Germany.; German Cancer Consortium (DKTK) and Bavarian Center for Cancer Research (BZKF), Partner Site Munich, Munich, Germany.; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany., Ingenerf M; Department of Radiology, University Hospital, LMU Munich, Munich, Germany., Unterrainer M; Department of Radiology, University Hospital, LMU Munich, Munich, Germany., Schmidt C; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany., Dekorsy FJ; Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany., Bartenstein P; Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.; Comprehensive Cancer Center München-LMU (CCCM LMU), LMU Munich, Munich, Germany., Ricke J; Department of Radiology, University Hospital, LMU Munich, Munich, Germany.; Comprehensive Cancer Center München-LMU (CCCM LMU), LMU Munich, Munich, Germany., von Bergwelt-Baildon M; German Cancer Consortium (DKTK) and Bavarian Center for Cancer Research (BZKF), Partner Site Munich, Munich, Germany.; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; Comprehensive Cancer Center München-LMU (CCCM LMU), LMU Munich, Munich, Germany., Subklewe M; Laboratory for Translational Cancer Immunology, Gene Center of the LMU Munich, Munich, Germany.; German Cancer Consortium (DKTK) and Bavarian Center for Cancer Research (BZKF), Partner Site Munich, Munich, Germany.; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; Comprehensive Cancer Center München-LMU (CCCM LMU), LMU Munich, Munich, Germany., Kunz WG; Department of Radiology, University Hospital, LMU Munich, Munich, Germany. wolfgang.kunz@med.lmu.de.; German Cancer Consortium (DKTK) and Bavarian Center for Cancer Research (BZKF), Partner Site Munich, Munich, Germany. wolfgang.kunz@med.lmu.de.; Comprehensive Cancer Center München-LMU (CCCM LMU), LMU Munich, Munich, Germany. wolfgang.kunz@med.lmu.de.
Publikováno v: Annals of hematology [Ann Hematol] 2024 Jan; Vol. 103 (1), pp. 259-268. Date of Electronic Publication: 2023 Oct 20.
Zobrazit plný text záznamu
2
Akademický článek
Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy.
Autor: Prasad R; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Rehman A; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Rehman L; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Darbaniyan F; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Blumenberg V; University Hospital, LMU Munich, Germany., Schubert ML; University Clinic Heidelberg, Germany., Mor U; Weizmann Institute of Science, Rehovot, Israel., Zamir E; German Cancer Research Center (DKFZ), Heidelberg, Germany., Schmidt S; German Cancer Research Center (DKFZ), Heidelberg, Germany., Hayase T; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Chia-Chi C; The University of Texas MD Anderson Cancer Center, United States., McDaniel LK; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Flores I; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Strati P; The University of Texas MD Anderson Cancer Center, United States., Nair R; The University of Texas MD Anderson Cancer Center, United States., Chihara D; The University of Texas MD Anderson Cancer Center, United States., Fayad LE; University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States., Ahmed S; The University of Texas MD Anderson Cancer Center, United States., Iyer SP; The University of Texas MD Anderson Cancer Center, United States., Wang ML; The University of Texas MD Anderson Cancer Center, United States., Jain P; The University of Texas MD Anderson Cancer Center, United States., Nastoupil LJ; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Westin JR; The University of Texas MD Anderson Cancer Center, United States., Arora R; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Turner JG; Moffitt Cancer Center, Tampa, Florida, United States., Khawaja F; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Wu R; The University of Texas MD Anderson Cancer Center, United States., Dennison JB; The University of Texas MD Anderson Cancer Center, United States., Menges M; Moffitt Cancer Center, Tampa, Florida, United States., Hidalgo-Vargas M; Moffitt Cancer Center, Tampa, Florida, United States., Reid KM; Moffitt Cancer Center, Tampa, Florida, United States., Davila ML; Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States., Dreger P; University Clinic Heidelberg, Heidelberg, Germany., Korell F; University Hospital Heidelberg, Heidelberg, Germany., Schmitt A; University Clinic Heidelberg, Germany., Tanner MR; The University of Texas MD Anderson Cancer Center, United States., Champlin RE; The University of Texas MD Anderson Cancer Center, United States., Flowers CR; The University of Texas MD Anderson Cancer Center, United States., Shpall EJ; The University of Texas MD Anderson Cancer Center, United States., Hanash S; The University of Texas MD Anderson Cancer Center, United States., Neelapu SS; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Schmitt M; University Clinic Heidelberg, Germany., Subklewe M; University Hospital, LMU Munich, Munich, Germany., Fahrmann J; The University of Texas MD Anderson Cancer Center, United States., Stein-Thoeringer C; University of Tuebingen, Tuebingen, Germany., Elinav E; Weizmann Institute of Science, Rehovot, Israel., Jain MD; Moffitt Cancer Center, Tampa, Florida, United States., Hayase E; The University of Texas MD Anderson Cancer Center, United States., Jenq RR; The University of Texas MD Anderson Cancer Center, United States., Saini NY; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.
Publikováno v: Blood [Blood] 2024 Oct 23. Date of Electronic Publication: 2024 Oct 23.
Zobrazit plný text záznamu
3
Akademický článek
Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy.
Autor: Voltin CA; Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. conrad-amadeus.voltin@uk-koeln.de., Paccagnella A; Department of Experimental, Diagnostic, and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy., Winkelmann M; Department of Radiology, University Hospital Munich, Ludwig Maximilian University Munich, Munich, Germany., Heger JM; Department of Internal Medicine I, Center for Integrated Oncology Aachen-Bonn-Cologne-Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.; Cologne Lymphoma Working Group (CLWG), Cologne, Germany., Casadei B; Department of Experimental, Diagnostic, and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy.; 'L. e A. Seràgnoli' Institute of Hematology, Scientific Institute for Research, Hospitalization, and Healthcare (IRCCS) 'Azienda Ospedaliero-Universitaria Di Bologna', University of Bologna, Bologna, Italy., Beckmann L; Department of Internal Medicine I, Center for Integrated Oncology Aachen-Bonn-Cologne-Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany., Herrmann K; Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.; German Cancer Consortium (DKTK) Partner Site Essen/Düsseldorf, Essen, Germany., Dekorsy FJ; Department of Nuclear Medicine, University Hospital Munich, Ludwig Maximilian University Munich, Munich, Germany., Kutsch N; Department of Internal Medicine I, Center for Integrated Oncology Aachen-Bonn-Cologne-Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.; Cologne Lymphoma Working Group (CLWG), Cologne, Germany., Borchmann P; Department of Internal Medicine I, Center for Integrated Oncology Aachen-Bonn-Cologne-Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.; Cologne Lymphoma Working Group (CLWG), Cologne, Germany., Fanti S; Department of Experimental, Diagnostic, and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy.; Division of Nuclear Medicine, Scientific Institute for Research, Hospitalization, and Healthcare (IRCCS) 'Azienda Ospedaliero-Universitaria Di Bologna', University of Bologna, Bologna, Italy., Kunz WG; Department of Radiology, University Hospital Munich, Ludwig Maximilian University Munich, Munich, Germany., Subklewe M; Department of Medicine III, Comprehensive Cancer Center Munich (CCCM), University Hospital Munich, Ludwig Maximilian University Munich, Munich, Germany.; Laboratory for Translational Cancer Immunology, Gene Center Munich, Ludwig Maximilian University Munich, Munich, Germany.; German Cancer Consortium (DKTK) and Bavarian Center for Cancer Research (BZKF) Partner Site Munich, Munich, Germany., Kobe C; Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany., Zinzani PL; Department of Experimental, Diagnostic, and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy.; 'L. e A. Seràgnoli' Institute of Hematology, Scientific Institute for Research, Hospitalization, and Healthcare (IRCCS) 'Azienda Ospedaliero-Universitaria Di Bologna', University of Bologna, Bologna, Italy., Stelljes M; Department of Medicine A-Hematology, Oncology, and Pneumology, West German Cancer Center (WTZ) Network Partner Site, University Hospital Münster, University of Münster, Münster, Germany., Roth KS; Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany., Drzezga A; Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany., Noppeney R; German Cancer Consortium (DKTK) Partner Site Essen/Düsseldorf, Essen, Germany.; Department of Hematology and Stem Cell Transplantation, West German Cancer Center (WTZ), University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Rahbar K; Department of Nuclear Medicine, University Hospital Münster, University of Münster, Münster, Germany., Reinhardt HC; German Cancer Consortium (DKTK) Partner Site Essen/Düsseldorf, Essen, Germany.; Department of Hematology and Stem Cell Transplantation, West German Cancer Center (WTZ), University Hospital Essen, University of Duisburg-Essen, Essen, Germany., von Tresckow B; German Cancer Consortium (DKTK) Partner Site Essen/Düsseldorf, Essen, Germany.; Department of Hematology and Stem Cell Transplantation, West German Cancer Center (WTZ), University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Seifert R; Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.; German Cancer Consortium (DKTK) Partner Site Essen/Düsseldorf, Essen, Germany.; Department of Nuclear Medicine, University Hospital Münster, University of Münster, Münster, Germany., Albring JC; Department of Medicine A-Hematology, Oncology, and Pneumology, West German Cancer Center (WTZ) Network Partner Site, University Hospital Münster, University of Münster, Münster, Germany., Blumenberg V; Department of Medicine III, Comprehensive Cancer Center Munich (CCCM), University Hospital Munich, Ludwig Maximilian University Munich, Munich, Germany.; Laboratory for Translational Cancer Immunology, Gene Center Munich, Ludwig Maximilian University Munich, Munich, Germany.; German Cancer Consortium (DKTK) and Bavarian Center for Cancer Research (BZKF) Partner Site Munich, Munich, Germany., Farolfi A; Division of Nuclear Medicine, Scientific Institute for Research, Hospitalization, and Healthcare (IRCCS) 'Azienda Ospedaliero-Universitaria Di Bologna', University of Bologna, Bologna, Italy., Flossdorf S; Institute for Medical Informatics, Biometry, and Epidemiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Gödel P; Department of Internal Medicine I, Center for Integrated Oncology Aachen-Bonn-Cologne-Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.; Cologne Lymphoma Working Group (CLWG), Cologne, Germany., Hanoun C; German Cancer Consortium (DKTK) Partner Site Essen/Düsseldorf, Essen, Germany.; Department of Hematology and Stem Cell Transplantation, West German Cancer Center (WTZ), University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Publikováno v: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2024 Apr; Vol. 51 (5), pp. 1361-1370. Date of Electronic Publication: 2023 Dec 20.
Zobrazit plný text záznamu
4
Akademický článek
Tracking non-relapse mortality after CAR T cell therapy.
Autor: Blumenberg V; Cellular Immunotherapy Program, Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Maus MV; Cellular Immunotherapy Program, Massachusetts General Hospital, Boston, MA, USA. mvmaus@mgh.harvard.edu.; Harvard Medical School, Boston, MA, USA. mvmaus@mgh.harvard.edu.
Publikováno v: Nature medicine [Nat Med] 2024 Sep; Vol. 30 (9), pp. 2413-2414.
Zobrazit plný text záznamu
5
Akademický článek
Efficacy and safety of bendamustine-containing bridging therapy in R/R LBCL patients receiving CD19 CAR T-cells.
Autor: Iacoboni G; Department of Hematology University Hospital Vall d'Hebron Barcelona Spain.; Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO) Barcelona Spain.; Department of Medicine Universitat Autònoma de Barcelona Bellaterra Spain., Sánchez-Salinas MA; Department of Hematology University Hospital Vall d'Hebron Barcelona Spain.; Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO) Barcelona Spain.; Department of Medicine Universitat Autònoma de Barcelona Bellaterra Spain., Rejeski K; Department of Medicine III University Hospital, LMU Munich Munich Germany.; Laboratory for Translational Cancer Immunology Gene Center of the LMU Munich Munich Germany.; Adult BMT and Cellular Therapy Service Memorial Sloan Kettering Cancer Center New York New York USA., Martín-López AÁ; Hematology Department Hospital Clínico Universitario de Salamanca, IBSAL, CIBERONC Salamanca Spain.; Centro de Investigación del Cáncer-IBMCC Salamanca Spain., Kwon M; Department of Hematology Hospital General Universitario Gregorio Marañón Madrid Spain.; Gregorio Marañón Health Research Institute (IiSGM) Madrid Spain., Navarro V; Oncology Data Science (ODySey) Group, Vall d'Hebron Institute of Oncology (VHIO) Barcelona Spain., Jalowiec KA; Hematology Department University College London Cancer Institute London United Kingdom.; Department of Hematology and Central Hematology Laboratory University Hospital of Bern Bern Switzerland., Hernani R; Haematology Department Hospital Clínico Universitario Valencia Spain.; INCLIVA Research Institute Valencia Spain., Reguera-Ortega JL; Hematology Department, Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC Universidad de Sevilla Sevilla Spain., Gallur L; Department of Hematology University Hospital Vall d'Hebron Barcelona Spain.; Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO) Barcelona Spain.; Department of Medicine Universitat Autònoma de Barcelona Bellaterra Spain., Blumenberg V; Department of Medicine III University Hospital, LMU Munich Munich Germany.; Laboratory for Translational Cancer Immunology Gene Center of the LMU Munich Munich Germany., Herrero-García M; Cancer Research Centre (IBMCC, USAL-CSIC), Institute for Biomedical Research of Salamanca (IBSAL) and Department of Medicine and Cytometry Service (NUCLEUS Research Support Platform) University of Salamanca (USAL) Salamanca Spain., Roddie C; Hematology Department University College London Cancer Institute London United Kingdom., Benzaquén A; Haematology Department Hospital Clínico Universitario Valencia Spain.; INCLIVA Research Institute Valencia Spain., Delgado-Serrano J; Hematology Department, Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC Universidad de Sevilla Sevilla Spain., Bailén R; Department of Hematology Hospital General Universitario Gregorio Marañón Madrid Spain.; Gregorio Marañón Health Research Institute (IiSGM) Madrid Spain., Carpio C; Department of Hematology University Hospital Vall d'Hebron Barcelona Spain.; Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO) Barcelona Spain.; Department of Medicine Universitat Autònoma de Barcelona Bellaterra Spain., Amat P; Haematology Department Hospital Clínico Universitario Valencia Spain.; INCLIVA Research Institute Valencia Spain., López-Corral L; Hematology Department Hospital Clínico Universitario de Salamanca, IBSAL, CIBERONC Salamanca Spain.; Centro de Investigación del Cáncer-IBMCC Salamanca Spain., Martín-Martín L; Cancer Research Centre (IBMCC, USAL-CSIC), Institute for Biomedical Research of Salamanca (IBSAL) and Department of Medicine and Cytometry Service (NUCLEUS Research Support Platform) University of Salamanca (USAL) Salamanca Spain., Bastos M; Department of Hematology Hospital General Universitario Gregorio Marañón Madrid Spain.; Gregorio Marañón Health Research Institute (IiSGM) Madrid Spain., Subklewe M; Department of Medicine III University Hospital, LMU Munich Munich Germany.; Laboratory for Translational Cancer Immunology Gene Center of the LMU Munich Munich Germany., O'Reilly M; Hematology Department University College London Cancer Institute London United Kingdom., Barba P; Department of Hematology University Hospital Vall d'Hebron Barcelona Spain.; Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO) Barcelona Spain.; Department of Medicine Universitat Autònoma de Barcelona Bellaterra Spain.
Publikováno v: HemaSphere [Hemasphere] 2024 Jun 26; Vol. 8 (7), pp. e86. Date of Electronic Publication: 2024 Jun 26 (Print Publication: 2024).
Zobrazit plný text záznamu
6
Akademický článek
Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy.
Autor: Iacoboni G; Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain.; Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain., Navarro V; Oncology Data Science (ODySey) Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Martín-López AÁ; Hematology Department, Hospital Clínico Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain.; Centro de Investigación del Cáncer-IBMCC, Salamanca, Spain., Rejeski K; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; Laboratory for Translational Cancer Immunology, Gene Center of the LMU Munich, Munich, Germany.; German Cancer Consortium (DKTK) and Bavarian Center for Cancer Research (BZKF), partner site Munich, Munich, Germany., Kwon M; Department of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.; Gregorio Marañón Health Research Institute (IiSGM), Madrid, Spain., Jalowiec KA; Hematology Department, University College London Cancer Institute, London, United Kingdom.; Department of Hematology and Central Hematology Laboratory, University Hospital of Bern, Bern, Switzerland., Amat P; Haematology Department, Hospital Clínico Universitario, Valencia, Spain.; INCLIVA Research Institute, Valencia, Spain., Reguera-Ortega JL; Hematology Department, Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC, Universidad de Sevilla, Sevilla, Spain., Gallur L; Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain.; Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain., Blumenberg V; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; Laboratory for Translational Cancer Immunology, Gene Center of the LMU Munich, Munich, Germany.; German Cancer Consortium (DKTK) and Bavarian Center for Cancer Research (BZKF), partner site Munich, Munich, Germany., Gutiérrez-Herrero S; Cancer Research Centre (IBMCC, USAL-CSIC), Institute for Biomedical Research of Salamanca (IBSAL) and Department of Medicine and Cytometry Service (NUCLEUS Research Support Platform), University of Salamanca (USAL), Salamanca, Spain., Roddie C; Hematology Department, University College London Cancer Institute, London, United Kingdom., Benzaquén A; Haematology Department, Hospital Clínico Universitario, Valencia, Spain.; INCLIVA Research Institute, Valencia, Spain., Delgado-Serrano J; Hematology Department, Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC, Universidad de Sevilla, Sevilla, Spain., Sánchez-Salinas MA; Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain.; Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain., Bailén R; Department of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.; Gregorio Marañón Health Research Institute (IiSGM), Madrid, Spain., Carpio C; Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain.; Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain., López-Corral L; Hematology Department, Hospital Clínico Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain.; Centro de Investigación del Cáncer-IBMCC, Salamanca, Spain., Hernani R; Haematology Department, Hospital Clínico Universitario, Valencia, Spain.; INCLIVA Research Institute, Valencia, Spain., Bastos M; Department of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.; Gregorio Marañón Health Research Institute (IiSGM), Madrid, Spain., O'Reilly M; Hematology Department, University College London Cancer Institute, London, United Kingdom., Martín-Martín L; Cancer Research Centre (IBMCC, USAL-CSIC), Institute for Biomedical Research of Salamanca (IBSAL) and Department of Medicine and Cytometry Service (NUCLEUS Research Support Platform), University of Salamanca (USAL), Salamanca, Spain., Subklewe M; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; Laboratory for Translational Cancer Immunology, Gene Center of the LMU Munich, Munich, Germany.; German Cancer Consortium (DKTK) and Bavarian Center for Cancer Research (BZKF), partner site Munich, Munich, Germany., Barba P; Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain.; Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain.
Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Jan 10; Vol. 42 (2), pp. 205-217. Date of Electronic Publication: 2023 Oct 24.
Zobrazit plný text záznamu
7
Akademický článek
Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL.
Autor: Blumenberg V; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany.; Laboratory for Translational Cancer Immunology, LMU Gene Center, LMU Munich, Munich, Germany.; German Cancer Consortium (DKTK), partner site Munich, Munich, Germany.; Bavarian Center for Cancer Research (BZKF), partner site Munich, Munich, Germany., Busch G; Laboratory for Translational Cancer Immunology, LMU Gene Center, LMU Munich, Munich, Germany., Baumann S; Laboratory for Translational Cancer Immunology, LMU Gene Center, LMU Munich, Munich, Germany., Jitschin R; Department of Internal Medicine 5, Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany.; Department for Hematology and Oncology, Otto-von-Guericke University, Magdeburg, Germany., Iacoboni G; Department of Hematology, Vall d'Hebron University Hospital, Experimental Hematology, Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Department of Medicine, Universitat Autònoma of Barcelona, Barcelona, Spain., Gallur L; Department of Hematology, Vall d'Hebron University Hospital, Experimental Hematology, Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Department of Medicine, Universitat Autònoma of Barcelona, Barcelona, Spain., Iraola-Truchuelo J; Department of Hematology, Vall d'Hebron University Hospital, Experimental Hematology, Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Hoster E; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany.; Institute for Medical Informatics, Biometry and Epidemiology, LMU Munich, Munich, Germany., Winkelmann M; Department of Radiology, LMU University Hospital, LMU Munich, Munich, Germany., Hellwig K; Department of Radiology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany., Schmidt C; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany., Frölich L; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany.; German Cancer Consortium (DKTK), partner site Munich, Munich, Germany., Tast B; Laboratory for Translational Cancer Immunology, LMU Gene Center, LMU Munich, Munich, Germany., Hildebrand F; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany., Rejeski K; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany.; Laboratory for Translational Cancer Immunology, LMU Gene Center, LMU Munich, Munich, Germany.; German Cancer Consortium (DKTK), partner site Munich, Munich, Germany.; Bavarian Center for Cancer Research (BZKF), partner site Munich, Munich, Germany., Dekorsy F; Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany., Schmidkonz C; Bavarian Center for Cancer Research (BZKF), partner site Munich, Munich, Germany.; Department of Nuclear Medicine, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany.; Institute for Medical Engineering, University of Applied Sciences Amberg-Weiden, Weiden, Germany., Bäuerle T; Department of Radiology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany., Kunz WG; Department of Radiology, LMU University Hospital, LMU Munich, Munich, Germany., Mougiakakos D; Department of Internal Medicine 5, Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany.; Department for Hematology and Oncology, Otto-von-Guericke University, Magdeburg, Germany.; Bavarian Cancer Research Center (BZKF), partner site Erlangen, Erlangen, Germany., Müller F; Department of Internal Medicine 5, Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany.; Bavarian Cancer Research Center (BZKF), partner site Erlangen, Erlangen, Germany., von Bergwelt-Baildon M; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany.; German Cancer Consortium (DKTK), partner site Munich, Munich, Germany.; Bavarian Center for Cancer Research (BZKF), partner site Munich, Munich, Germany., Barba P; Department of Hematology, Vall d'Hebron University Hospital, Experimental Hematology, Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Department of Medicine, Universitat Autònoma of Barcelona, Barcelona, Spain., Bücklein VL; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany.; Laboratory for Translational Cancer Immunology, LMU Gene Center, LMU Munich, Munich, Germany.; Bavarian Center for Cancer Research (BZKF), partner site Munich, Munich, Germany., Mackensen A; Department of Internal Medicine 5, Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany.; Bavarian Cancer Research Center (BZKF), partner site Erlangen, Erlangen, Germany., Völkl S; Department of Internal Medicine 5, Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany.; Bavarian Cancer Research Center (BZKF), partner site Erlangen, Erlangen, Germany., Subklewe M; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany.; Laboratory for Translational Cancer Immunology, LMU Gene Center, LMU Munich, Munich, Germany.; German Cancer Consortium (DKTK), partner site Munich, Munich, Germany.; Bavarian Center for Cancer Research (BZKF), partner site Munich, Munich, Germany.
Publikováno v: Blood advances [Blood Adv] 2023 Nov 28; Vol. 7 (22), pp. 6844-6849.
Zobrazit plný text záznamu
8
Akademický článek
Functional connectivity MRI provides an imaging correlate for chimeric antigen receptor T-cell-associated neurotoxicity.
Autor: Stoecklein S; Department of Radiology, University Hospital, LMU Munich, Munich, Germany., Wunderlich S; Department of Radiology, University Hospital, LMU Munich, Munich, Germany., Papazov B; Department of Radiology, University Hospital, LMU Munich, Munich, Germany., Winkelmann M; Department of Radiology, University Hospital, LMU Munich, Munich, Germany., Kunz WG; Department of Radiology, University Hospital, LMU Munich, Munich, Germany., Mueller K; Department of Neurology, University Hospital, LMU Munich, Munich, Germany., Ernst K; Department of Neurology, University Hospital, LMU Munich, Munich, Germany., Stoecklein VM; Department of Neurosurgery, University Hospital, LMU Munich, Munich, Germany.; German Cancer Consortium (DKTK), partner site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany., Blumenberg V; German Cancer Consortium (DKTK), partner site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; Laboratory for Translational Cancer Immunology, Gene Center, LMU Munich, Munich, Germany., Karschnia P; Department of Neurosurgery, University Hospital, LMU Munich, Munich, Germany.; German Cancer Consortium (DKTK), partner site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany., Bücklein VL; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; Laboratory for Translational Cancer Immunology, Gene Center, LMU Munich, Munich, Germany.; Bavarian Cancer Research Center (BZKF), Erlangen, Germany., Rejeski K; German Cancer Consortium (DKTK), partner site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Laboratory for Translational Cancer Immunology, Gene Center, LMU Munich, Munich, Germany.; Bavarian Cancer Research Center (BZKF), Erlangen, Germany.; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany., Schmidt C; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany., von Bergwelt-Baildon M; German Cancer Consortium (DKTK), partner site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; Bavarian Cancer Research Center (BZKF), Erlangen, Germany., Tonn JC; Department of Neurosurgery, University Hospital, LMU Munich, Munich, Germany.; German Cancer Consortium (DKTK), partner site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany., Ricke J; Department of Radiology, University Hospital, LMU Munich, Munich, Germany.; Department of Neurology, University Hospital, LMU Munich, Munich, Germany., Liu H; Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA, USA.; Department of Neuroscience, Medical University of South Carolina, Charleston, SC, USA., Remi J; Department of Radiology, University Hospital, LMU Munich, Munich, Germany.; Department of Neurology, University Hospital, LMU Munich, Munich, Germany., Subklewe M; German Cancer Consortium (DKTK), partner site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; Laboratory for Translational Cancer Immunology, Gene Center, LMU Munich, Munich, Germany.; Bavarian Cancer Research Center (BZKF), Erlangen, Germany., von Baumgarten L; Department of Neurology, University Hospital, LMU Munich, Munich, Germany.; Department of Neurosurgery, University Hospital, LMU Munich, Munich, Germany.; German Cancer Consortium (DKTK), partner site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Bavarian Cancer Research Center (BZKF), Erlangen, Germany., Schoeberl F; Department of Neurology, University Hospital, LMU Munich, Munich, Germany.; German Center for Vertigo and Balance Disorders, University Hospital, LMU Munich, Munich, Germany.
Publikováno v: Neuro-oncology advances [Neurooncol Adv] 2023 Oct 24; Vol. 5 (1), pp. vdad135. Date of Electronic Publication: 2023 Oct 24 (Print Publication: 2023).
Zobrazit plný text záznamu
9
Akademický článek
Modification of Lugano criteria by pre-infusion tumor kinetics improves early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapy.
Autor: Winkelmann M; Department of Radiology, University Hospital, LMU Munich, Munich, Germany., Blumenberg V; Department of Hematology and Oncology, University Hospital Munich Campus Grosshadern, Munich, Germany.; German Cancer Consortium, Heidelberg, Germany., Rejeski K; Department of Hematology and Oncology, University Hospital Munich Campus Grosshadern, Munich, Germany.; German Cancer Consortium, Heidelberg, Germany., Quell C; Department of Radiology, University Hospital, LMU Munich, Munich, Germany., Bücklein V; Department of Hematology and Oncology, University Hospital Munich Campus Grosshadern, Munich, Germany.; German Cancer Consortium, Heidelberg, Germany., Ingenerf M; Department of Radiology, University Hospital, LMU Munich, Munich, Germany., Unterrainer M; Department of Radiology, University Hospital, LMU Munich, Munich, Germany., Schmidt C; Department of Hematology and Oncology, University Hospital Munich Campus Grosshadern, Munich, Germany.; German Cancer Consortium, Heidelberg, Germany., Dekorsy FJ; Department of Nuclear Medicine, University Hospital, Munich, Germany., Bartenstein P; German Cancer Consortium, Heidelberg, Germany.; Department of Nuclear Medicine, University Hospital, Munich, Germany., Ricke J; Department of Radiology, University Hospital, LMU Munich, Munich, Germany.; German Cancer Consortium, Heidelberg, Germany., von Bergwelt-Baildon M; Department of Hematology and Oncology, University Hospital Munich Campus Grosshadern, Munich, Germany.; German Cancer Consortium, Heidelberg, Germany., Subklewe M; Department of Hematology and Oncology, University Hospital Munich Campus Grosshadern, Munich, Germany.; German Cancer Consortium, Heidelberg, Germany., Kunz WG; Department of Radiology, University Hospital, LMU Munich, Munich, Germany wolfgang.kunz@med.lmu.de.; German Cancer Consortium, Heidelberg, Germany.
Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2023 Oct; Vol. 11 (10).
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje